Connection

David Taber to Bevacizumab

Back to Details
This is a "connection" page, showing publications David Taber has written about Bevacizumab.
David Taber
Connection Strength
0.025
Bevacizumab
  1. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer. 2013 May; 14(3):224-9.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.